NCT05134532View on ClinicalTrials.gov

Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 24, 2021

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2024

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

regorafenib

Regorafenib 160 mg orally every day for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off) plus best supportive care

Trial Locations (2)

13520

CHA Bundang Medical Center, Seongnam-si

Unknown

Asan Medical Center, Seoul

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

CHA University

OTHER